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EDITORIAL
The  role of transbronchial  biopsy  in  the diagnosis  of diffuse
parenchymal lung  diseases:  Con
O  papel  da  biopsia  transbrônquica  no  diagnóstico  das  doenc¸as difusas  do
parênquima  pulmonar:  Contra
In  order  to  engage  in  a  focused  pro/con  debate,  it  is  use-
ful  to  summarize  key  points  of  agreement,  before  reviewing
areas  that  remain  contentious.  It  would  be  folly  to  deny
that  in  certain  scenarios  in  diffuse  parenchymal  lung  disease
(DPLD),  the  transbronchial  biopsy  (TBLB)  has  an  invaluable
diagnostic  role.  In  DPLD,  histological  support  for  a  spe-
ciﬁc  diagnosis  can  be  obtained  using  TBLB  in  29--79%  of
cases.1 This  wide  range  reﬂects  the  multiplicity  of  fac-
tors  inﬂuencing  the  yield  of  the  procedure,  including  the
distribution  of  the  lesion  (focal  or  diffuse),  status  of  the
immune  system  of  the  patient,  small  size  of  the  obtained
samples,  confounding  due  to  crush  artifacts  and  failure  to
penetrate  beyond  the  peribronchial  sheath.2,3 Despite  these
limitations,  we  can  all  agree,  based  on  diagnostic  yields
of  65--90%  in  selected  conditions,1 that  TBLB  is  an  appro-
priate  ﬁrst  biopsy  procedure  in  many  patients  in  whom
bronchocentric  DPLDs  are  suspected,  especially  sarcoido-
sis  and  lympangitis  carcinomatosis.  In  other  disorders,  TBLB
appearances  are  not  diagnostically  deﬁnitive  in  isolation  but
allow  the  formulation  of  a  conﬁdent  diagnosis  when  inte-
grated  with  clinical  data  (including  bronchoalveolar  lavage)
and  radiologic  ﬁndings:  this  applies  especially  to  cryptogenic
organizing  pneumonia4 and,  less  often,  to  hypersensitiv-
ity  pneumonitis.  However,  when  it  comes  to  the  diagnosis
of  individual  idiopathic  interstitial  pneumonias  (IIPs),  a
very  different  consensus  emerges.  In  the  recently  published
guidelines  for  the  diagnosis  of  idiopathic  pulmonary  ﬁbrosis
(IPF)5 it  was  unanimously  concluded  that  TBLB  should  not  be
used  to  provide  histologic  support  for  a  diagnosis  of  IPF.  We
explore  the  rationale  behind  this  recommendation,  which
is  diametrically  opposed  to  the  ‘‘pro’’  view  in  these  paired
editorials.
The  practical  value  of  making  a  conﬁdent  diagnosis  is  to
provide  accurate  information  on  the  likely  natural  history
and/or  treated  course  of  disease  in  an  individual  patient.
Essentially,  it  can  be  argued  that  in  DPLD,  ‘‘diagnosis  is  prog-
nosis’’.  No  diagnostic  test  has  consistent  value  in  suspected
IIP  unless  it  helps  materially  in  the  identiﬁcation  of  IPF,  the
most  prevalent  IIP.  A  diagnosis  of  IPF  has  vital  prognostic  sig-
niﬁcance  as  the  other  IIPs  have,  on  average,  a  much  better
treated  outcome.5 At  present,  it  is  accepted  that  the  diag-
nosis  of  IPF  can  be  based  on  typical  HRCT  appearances  and
a  compatible  clinical  picture  in  at  least  50%  of  IPF  cases.1
In  the  remaining  cases,  histolgical  conﬁrmation  of  a  pat-
tern  of  usual  interstitial  pneumonia  (UIP)  is  required,  with
the  ﬁnal  diagnosis  made  by  consensus  between  histopatholo-
gists,  radiologists  and  clinicians.5 The  histological  pattern  of
UIP  is  characterized  by  subpleural  predominance  of  disease,
temporal  heterogeneity  (i.e.  areas  of  established  ﬁbrosis
juxtaposed  with  areas  of  active  ﬁbrosis  and  normal  lung)  and
the  presence  of  ﬁbroblastic  foci.5 But  which  type  of  biopsy
provides  sufﬁciently  accurate  information  for  the  formula-
tion  of  a diagnosis  of  IPF?
Until  recently,  it  was  viewed  as  axiomatic  that  a  sur-
gical  lung  biopsy  (SLB)  was  the  ‘gold  standard’  diagnostic
procedure  in  DPLD.  With  the  development  of  a  multidis-
ciplinary  approach  to  diagnosis,  it  is  now  acknowledged
that  histologic  information  must  be  reconciled  with  clini-
cal  and  radiologic  data,  but  the  central  role  of  a diagnostic
SLB  in  selected  patients  has  not  been  seriously  questioned.
None  the  less,  the  limitations  of  SLB  should  be  acknowl-
edged.  SLB  cannot  be  performed  in  many  patients  because
often  advanced  age,  severity  of  the  disease  and  pres-
ence  of  co-morbidities  are  major  constraints.  Moreover,  the
interpretation  of  SLB  is  subject  to  signiﬁcant  interobserver
variation.  In  a  study  undertaken  by  pathologists  with  spe-
cialist  expertise  in  the  ﬁeld  of  DPLD,  the  level  of  agreement
on  the  ﬁrst  choice  diagnosis  was  at  the  lower  limit  of  what
would  be  accepted  as  clinically  useful,  as  judged  by  the
kappa  coefﬁcient  of  agreement.6 Lastly,  there  is  the  prob-
lem  of  ‘‘sampling  error’’,  consisting  of  the  identiﬁcation  of
a  histologic  pattern  that  is  not  representative  of  the  pre-
dominant  process.7,8 In  IPF,  areas  of  ﬁbrotic  non  speciﬁc
interstitial  pneumonia  (NSIP)  often  exist  and  if  captured  at
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SLB,  an  incorrect  ﬁnal  diagnosis  of  NSIP  may  be  made  with
adverse  effects  on  the  accuracy  of  prognostication,  selec-
tion  of  appropriate  therapy  and  planning  of  transplantation.
Plainly,  an  alternative  mode  of  biopsy  that  overcomes
these  problems  with  substantial  loss  of  diagnostic  accuracy
would  be  invaluable  and  it  is  this  unmet  need  that  justiﬁes
reappraisal  of  the  role  of  TBLB.  But  is  TBLB  intrinsically  reli-
able  in the  diagnosis  of  IPF  and  other  IIPs,  and  does  it  address
the  limitations  of  SLB  listed  above?  It  is  our  contention  that
the  answer  to  both  questions  is  resoundingly  negative.
In  reality,  it  is  difﬁcult  to  make  deﬁnitive  statements
on  the  accuracy  of  TBLB  in  the  IIPs  because  of  the  lack
of  a  properly  conducted  diagnostic  study,  reﬂecting  the
widespread  view  that  IPF  cannot  be  diagnosed  with  conﬁ-
dence  using  small  TBLB  samples.  This  perception  is  pivotal
because  a  tentative  diagnosis,  however  accurate,  is  of  lit-
tle  value  in  the  formulation  of  a  logical  plan.  As  long  as
this  view  remains  prevalent,  TBLB  simply  cannot  provide  the
same  diagnostic  weight  as  SLB.  However,  it  is  worth  con-
sidering  the  study  of  Berbescu  et  al.,  if  only  to  make  the
point  that  this  most  insubstantial  of  ‘‘diagnostic  studies’’
cannot  be  used  to  argue  for  a  diagnostic  role  for  TBLB  in
IPF.9 The  authors  retrospectively  evaluated  TBLB  from  21
patients  with  surgical  biopsy  proven  UIP  and  from  1 patient
with  clinical  and  radiological  ﬁndings  of  IPF/UIP.  They  con-
cluded  that  7 of  22  patients  had  features  ‘‘diagnostic’’  of
UIP  such  as  patchy  interstitial  ﬁbrosis  along  with  ﬁbrob-
lastic  foci  and/or  honeycomb  change,  a  rather  miserable
yield  of  approximately  30%.  From  this  small  study,  they
reach  the  inexplicable  conclusion  that  TBLB  may  be  use-
ful  in  conﬁrming  the  diagnosis  of  UIP.  The  ﬂaw  in  the  logic
is  that  the  only  patients  included  in  this  study  had  a  ﬁnal
histologic  diagnosis  of  UIP  without  ancillary  SLB  features  sug-
gestive  of  HP  or  alternative  disorders  such  as  connective
tissue  diseases.  The  authors  are  aware  of  patients  ulti-
mately  proven  histologically  to  have  sarcoidosis,  in  which
TBLB  ﬁndings  of  honeycombing  and  temporal  heterogene-
ity  were  ‘‘strongly  suggestive  of  UIP’’  (as  described  above).
Such  patients  could  not,  by  deﬁnition,  have  been  included
in  the  study  of  Berbescu.  A  UIP  pattern  is  not  infrequent
in  hypersensitivity  pneumonitis  (HP)  but  the  presence  of
areas  of  bronchocentric  inﬂammation  and/or  poorly  formed
granulomata  (which  are  often  sparse  in  large  SLB  samples)
are  key  diagnostic  features  which  would,  once  again,  have
excluded  these  cases  from  the  study  discussed  above.  A  TBLB
pattern  ‘‘compatible  with  UIP’’  will  be  actively  misleading
if  additional  features  indicative  of  HP,  sarcoidosis  or  other
DPLDs  are  missed  in  small  TBLB  samples.  In  essence,  the
statement  that  TBLB  appearances  were  indicative  of  UIP  in
cases  proven  by  SLB  to  have  UIP  has  negligeable  diagnos-
tic  value.  The  pivotal  problem  of  false  positive  diagnosis  is
not  acknowledged  in  the  study  of  Berbescu,  which  cannot
be  considered  as  a  true  diagnostic  study.  Indeed,  the  partic-
ipating  histopathologists  were  not  blinded  to  the  diagnosis
of  UIP  prior  to  reviewing  the  TBLB  samples!
Thus,  no  data  exist  to  suggest  that  TBLB  might  provide
useful  support  for  a  diagnosis  of  IPF  but  does  this  diagnostic
modality  address  the  limitations  of  SLB?  On  the  face  of  it,
TBLB  is  a  safer  procedure  as  it  does  not  require  general  anes-
thesia,  has  an  overall  mortality  of  0.1%  which  is  lower  than
that  of  SLB  (approximately  1%)  and  can  be  performed  as  an
outpatient  procedure.10--12 TBLB  can  be  performed  in  some
patients  not  ﬁt  for  SLB  due  to  disease  severity  and  presence
of  co-morbidities.  However,  even  this  apparent  advantage
can  be  questioned  as  inaccurate  diagnoses  carry  their  own
dangers.  Moreover,  the  other  limitations  of  SLB  --  diagnos-
tic  interobserver  variation  and  sampling  error  --  are  present
to  a much  greater  extent  with  the  interpretation  of  TBLB
samples.
In  the  current  literature,  there  are  no  studies  of  observer
variation  in  the  histologic  interpretation  of  TBLB  samples.
However,  the  level  of  agreement  between  expert  pul-
monary  pathologists  is  only  moderate  with  regard  to  the
interpretation  of  SLB  samples6,13 and  must  necessarily  be
more  problematic  for  TBLB.  The  small  size  of  the  TBLB
and  the  need  to  integrate  TBLB  appearances  from  several
biopsies  into  an  overall  histologic  pattern  carries  its  own
variability,  which  must  be  added  to  the  overall  variabil-
ity  of  histologic  interpretation.  The  problem  of  discordance
between  observers  is  compounded  by  the  fact  that  small
TBLB  samples  do  not  allow  an  assessment  of  the  extent  and
distribution  of  ﬁbrosis  within  the  biopsied  lobe.  These  lim-
itations  can  only  be  more  problematic  for  less  experienced
histopathologists,  seeking  to  make  a  conﬁdent  diagnosis  of
UIP  using  TBLB  samples,  applying  the  criteria  proposed  by
Berbescu  et  al.9
Similarly,  the  problem  of  ‘‘sampling  error’’  can  only  be
increased  with  the  diagnostic  use  of  TBLB.  In  IPF,  it  is  now
well  recognized  that  in  many  patients,  there  are  areas
of  NSIP-like  change.  The  ﬁnding  of  NSIP  in  one  lobe  and
UIP  in  another  lobe  is  not  infrequent.  Attempts  to  synthe-
size  a  histologic  diagnosis  from  TBLB,  taken  from  only  one
lobe,  cannot  properly  address  this  problem.  Furthermore,
a  histologic  pattern  of  UIP  may  also  be  present  in  chronic
hypersensitivity  pneumonitis  or  rheumatoid  lung.  Ancillary
features  suggestive  of  these  disorders  are  often  very  lim-
ited  in  extent  and  are  unlikely  to  be  detected  in  a  TBLB
specimen.  For  example,  the  diagnosis  of  hypersensitivity
pneumonitis  will  be  strongly  suspected  when  a UIP  pattern
is  bronchocentric  in  distribution  and  there  are  occasional
poorly  formed  granulomas,  which  will  often  be  detected
only  with  the  examination  of  multiple  biopsy  ﬁelds.  Simi-
larly,  in  rheumatoid  lung,  the  suggestive  observation  that
lymphoid  follicles  are  unusually  prominent  requires  exami-
nation  of  suitably  extensive  biopsy  tissue.  Whether  or  not
these  key  features  are  captured  by  TBLB  can  only  be  a
matter  of  chance.  The  conclusion  is  inescapable:  whatever
‘‘sampling  error’’  exists  with  the  performance  of  a  single
SLB  specimen  can  only  be  ampliﬁed  by  the  diagnostic  use  of
TBLB.
In  an  attempt  to  overcome  these  limitations,  it  has  been
proposed  that  the  use  of  larger  forceps  via  rigid  bron-
choscope  would  increase  the  diagnostic  yield  of  TBLB14
and  avoid  crush  artifacts.  In  a keynote  series,  the  authors
observed  that  in  74  out  of  95  patients  with  DPLD,  a  diag-
nosis  was  made  with  the  use  of  large  forceps,  compared
to  62  out  of  95  with  the  use  of  smaller  forceps.  How-
ever,  there  was  one  major  limitation.  In  the  74  patients
in  whom  the  large  biopsy  technique  was  considered  to  be
successful,  the  underlying  diagnoses  were  forms  of  inﬂam-
matory  DPLD.  By  contrast,  in  the  21  undiagnosed  cases  in
this  series,  the  most  frequent  diagnosis  at  SLB  was  UIP/IPF,
followed  by  ﬁbrotic  NSIP  and  chronic  hypersensitivity  pneu-
monitis.  Thus,  although  undoubtedly  promising,  this  method
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is  yet  to  be  validated  in  the  diagnosis  of  IPF  or  the  other
IIPs.
In  the  ﬁeld  of  DPLDs,  the  accurate  identiﬁcation  of  IPF
remains  the  cardinal  diagnostic  challenge.  In  other  disor-
ders,  anti-inﬂammatory  treatment  is  often  successful.  In  IPF,
long-term  stabilization  of  disease  is  not  a  realistic  goal  and
enrolment  in  trials  of  novel  therapeutic  agents  is  strongly
recommended  in  recent  guideline  statements.  This  crucial
treatment  dichotomy  should  not  be  based  on  biopsy  samples
which  are  small  in  size  and  must  necessarily  be  associated
with  major  interobserver  variation  and  sampling  error.  At
present,  TBLB  samples,  although  useful  in  other  contexts,
are  patently  inadequate  for  this  purpose.
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